LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Elenco Azioni・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

35.38 -1.45

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

35.28

Massimo

35.69

Metriche Chiave
By Trading Economics
Entrata	-5M -128M
Vendite	6.8M 11M
EPS	-1.23
Margine di Profitto	-1,191.029
Dipendenti	594
EBITDA	-18M -139M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+140.51% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-469M 3.9B
Apertura precedente	36.83
Chiusura precedente	35.38

Notizie sul Sentiment di mercato

By Acuity

50%

161 / 344 Classifica in Healthcare

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 mag 2026, 23:08 UTC

Acquisizioni, Fusioni, Takeovers

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 mag 2026, 23:06 UTC

Acquisizioni, Fusioni, Takeovers

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 mag 2026, 20:53 UTC

Utili

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 mag 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

29 mag 2026, 20:33 UTC

Discorsi di Mercato

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 mag 2026, 20:11 UTC

Utili

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mag 2026, 19:47 UTC

Utili

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 mag 2026, 19:36 UTC

Discorsi di Mercato

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 mag 2026, 19:34 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

29 mag 2026, 19:34 UTC

Discorsi di Mercato

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 mag 2026, 19:22 UTC

Discorsi di Mercato

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 mag 2026, 19:05 UTC

Acquisizioni, Fusioni, Takeovers

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 mag 2026, 18:19 UTC

Discorsi di Mercato

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 mag 2026, 18:12 UTC

Acquisizioni, Fusioni, Takeovers

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 mag 2026, 18:11 UTC

Discorsi di Mercato

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 mag 2026, 18:10 UTC

Discorsi di Mercato

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 mag 2026, 17:55 UTC

Utili

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mag 2026, 17:55 UTC

Discorsi di Mercato

NEAR Protocol Nearly Doubles in May -- Market Talk

29 mag 2026, 17:38 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 mag 2026, 17:00 UTC

Utili

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 mag 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

29 mag 2026, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

29 mag 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

29 mag 2026, 16:02 UTC

Discorsi di Mercato

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 mag 2026, 15:55 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

29 mag 2026, 15:55 UTC

Discorsi di Mercato

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29 mag 2026, 15:50 UTC

Acquisizioni, Fusioni, Takeovers

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29 mag 2026, 15:50 UTC

Acquisizioni, Fusioni, Takeovers

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29 mag 2026, 15:40 UTC

Discorsi di Mercato

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29 mag 2026, 15:20 UTC

Discorsi di Mercato

Canada's Economy Not Looking All That Bright -- Market Talk

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

140.51% in crescita

Previsioni per 12 mesi

Media 85.5 USD 140.51%

Alto 97 USD

Basso 67 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

161 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.